Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Erian

Neurology Augusta, GA Medical Doctor

NPI 1902167323 CMS profile 221788

1120 15Th St, Augusta, GA 30912

Open in the dashboard

General payments

$12,150

555 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Erian of Augusta, GA is reported in the CMS Open Payments database as having received $12,150 across 555 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,694 68
2024 General $1,683 75
2023 General $2,254 86
2022 General $2,145 95
2021 General $1,679 77
2020 General $1,293 69
2019 General $1,402 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Erian
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Andrew Erian were reported at $1,694. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Andrew Erian Neurology median Middle half National median
2019 $1,402 $474 $118–$2,177 $163
2020 $1,293 $367 $82–$2,309 $114
2021 $1,679 $438 $104–$2,547 $132
2022 $2,145 $442 $103–$2,388 $149
2023 $2,254 $464 $119–$2,312 $160
2024 $1,683 $468 $119–$2,323 $164
2025 $1,694 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,411 129 payments
  2. UCB, Inc. $727 38 payments
  3. EMD Serono, Inc. $595 15 payments
  4. Lilly USA, LLC $592 36 payments
  5. Allergan Inc. $551 26 payments
  6. Eisai Inc. $438 20 payments
  7. Sunovion Pharmaceuticals Inc. $322 12 payments
  8. Amgen Inc. $314 16 payments
  9. Novartis Pharmaceuticals Corporation $306 21 payments
  10. ACADIA Pharmaceuticals Inc $285 15 payments
  11. Other $4,611 227 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,116 553 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $35 2 payments
Products named General payments · program years 2019–2025
  1. BOTOX Botox Therapeutic $1,663 60 payments
  2. UBRELVY Neuroscience $1,229 39 payments
  3. AIMOVIG $569 34 payments
  4. QULIPTA $567 28 payments
  5. ZEPOSIA $525 26 payments
  6. BOTOX Hyperhydrosis $525 23 payments
  7. APTIOM $459 19 payments
  8. Briviact $455 23 payments
  9. UBRELVY Neuroscience $331 14 payments
  10. EMGALITY $321 20 payments
  11. Other $5,978 295 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

121

Median for Neurology: 833

Drug cost

$15,931

Median for Neurology: $202,670

Branded share of claims

19.8%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Qulipta Atogepant Brand 13 $13,029
Levetiracetam Generic 32 $1,708
Memantine Hcl Generic 20 $411
Donepezil Hcl Generic 28 $408
Carbidopa-Levodopa Carbidopa/Levodopa Brand 11 $192
Gabapentin Generic 17 $182

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$93,954

Medicare's payments for the services billed

Medicare patients

431

Average age 77

Services billed

961

233 women, 198 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 48%
Ischemic heart disease 38%
Depression 36%
Alzheimer's or dementia 34%
COPD 33%
Heart failure 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $519
$519 — —
UBRELVY
  • AbbVie, Inc. $138
$138 — —
Briviact
  • UCB, Inc. $110
$110 — —
APTIOM
  • Sumitomo Pharma America, Inc. $102
$102 — —
Nayzilam
  • UCB, Inc. $82
$82 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

555 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record